Маалокс®

General characteristics. Structure:

Active agents: magnesium hydroxide (in the form of gel) - 4,00 g, aluminum hydroxide (in the form of gel) - 3,50 g;
excipients: Acidum hydrochloricum of 10%, citric acid monohydrate, a peppermint of leaves oil, Mannitolum, methylparahydroxybenzoate, пропилпарагидроксибензоат, sodium saccharinate, sorbitol of 70%, hydrogen peroxide of 30%, the water purified.
Description: the white, or almost white, reminding milk liquid with a mint smell.

Pharmacological properties:

Pharmacodynamics. Aluminum hydroxide and magnesium hydroxide neutralize free hydrochloric acid of a gastric juice, without causing its secondary hypersecretion. Besides, increase рН a gastric juice at administration of drug of Maaloks® leads to decrease of the activity of pepsin in a gastric juice. Drug possesses also adsorbing and enveloping action thanks to which impact of disturbing factors on a mucous membrane of a gullet and a stomach decreases.

Pharmacokinetics. Magnesium hydroxide and aluminum hydroxide are considered as antacids of local action. Because of low absorption have no systemic action.

Indications to use:

- A peptic ulcer of a stomach and duodenum in an aggravation phase.
- Acute gastroduodenit, chronic gastroduodenit with the normal or increased secretory function in an aggravation phase.
- Hernia of an esophageal opening of a diaphragm, reflux esophagitis.
- The dispeptic phenomena, such, as, discomfort, a gastralgia, heartburn (after the excess use of ethanol, nicotine, coffee, reception of medicines, errors in a diet).
- Discomfort or pains in epigastriums, heartburn, an acid eructation after errors in a diet, excess alcohol intake, coffee, nicotine, etc.

Route of administration and doses:

Inside. Before use the bottle should be stirred up.
Adults and teenagers are more senior than 15 years: on 15 ml (1 tablespoon) 3-4 times a day through 1k2 hour after food and for the night. The dose should not exceed 6 tablespoons a day. At a reflux esophagitis drug is accepted through short time after food. The course of treatment should not exceed 2-3 months. At incidental use (for example, at discomfort after errors in a diet) accept 15 ml once.

Features of use:

It is necessary to observe a 2-hour interval between use the drug Maaloks® and other drugs and a 4-hour interval between administration of drug of Maaloks® and ftorkhinolon (see the section "Interaction with Other Medicines").
It is necessary to avoid long purpose of the drug Maaloks® at renal failures.
Aluminum hydroxide at the low content of phosphates in food can lead to development of phosphatic insufficiency in an organism. Therefore at hydroxide aluminum use, especially long, it is necessary to provide sufficient intake of phosphates with food.

Side effects:

At observance of the recommended dosing mode side effects meet seldom.
There can sometimes be diarrhea, a lock, nausea, vomiting, change of flavoring feelings.
At long reception of high doses can arise a hypophosphatemia (especially at the low content of phosphates in food), a hypercalcuria, a nephrocalcinosis, a hypocalcemia, osteoporosis, osteomalacy, a renal failure.
At patients with the accompanying renal failure are possible: increase in plasma concentration of magnesium and/or aluminum, thirst development, lowering of arterial pressure, hyporeflexia.
At prolonged use of high doses at patients with a renal failure development of encephalopathy, dementia, microcytic anemia is in rare instances possible.

Interaction with other medicines:

- Skhinidin
At simultaneous use with quinidine increase in serumal concentration of quinidine and development of overdose of quinidine is possible.
- With blockers Н^гистаминовых of receptors, propranolol, atenololy, metoprololy, chloroquine, prostacyclins, diflunisaly, the digoxin, bisfosfonata accepted inside by Ethambutolum and an isoniazid, ftorkhinolona, sodium fluoride, glucocorticosteroids (it is described for Prednisolonum and dexamethasone), indometacin, ketokonazoly, linkozamida, fenotiazinovy neuroleptics, Penicillaminum, iron salts, tetracyclines, acetylsalicylic acid (and other salicylates), phosphorus food to additives, feksofenadiny, lansoprazoly, left thyroxine
At a concomitant use with the drug Maaloks® absorption of the listed above drugs in digestive tract decreases. In case of a 2-hour interval between reception of these drugs and the drug Maalok® and a 4-hour interval between reception of ftorkhinolon and the drug Maaloks® in most cases this undesirable interaction can be avoided.
- With salicylates
At a concomitant use of salicylates and the drug Maaloks® salicylate excretion with urine as a result of alkalization of urine under the influence of the drug Maaloks® increases.
- With citrates
At a hydroxide aluminum combination to citrates increase in plasma concentration of aluminum, in particular, at patients with a renal failure is possible.

Contraindications:

- Heavy renal failure.
- Hypersensitivity to drug components.
- Intolerance of fructose (because of existence in composition of drug of sorbitol).
- Children's and teenage age up to 15 years.
- Hypophosphatemia. With care
- At a renal failure at long reception perhaps increases in plasma concentration of magnesium and aluminum. At these patients at prolonged use of drug in high doses development of encephalopathy, dementia, microcytic anemia is possible.
- At the patients with a porphyria who are on a hemodialysis; at pregnancy and a lactation (see. "Pregnancy and lactation").
- At Alzheimer's disease.
- At the low content of phosphates in food (risk of development of phosphatic insufficiency).
Pregnancy and period of a lactation
At animals accurate instructions on existence of teratogenic effect at aluminum hydroxide and magnesium hydroxide are not received. Currently no specific teratogenic effects when using the drug Maaloks® are revealed during pregnancy, however, in connection with insufficiency of clinical experience, its use during pregnancy is possible, only if the potential advantage of its use for mother justifies potential risk for a fruit.
During administration of drug of Maaloks® of the termination of feeding the breast does not require.

Storage conditions:

To store at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity 3 years.
Not to apply after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

Suspension for intake.
On 250 ml of drug in a bottle of dark glass with an aluminum cover. On 1 bottle together with the application instruction place in a cardboard pack.